Breaking News Instant updates and real-time market news.

PFE

Pfizer

$37.28

0.73 (2.00%)

, ABBV

AbbVie

$88.64

1.03 (1.18%)

06:50
11/18/19
11/18
06:50
11/18/19
06:50

Pfizer announces FDA approval of biosimilar ABRILADA

Pfizer (PFE) announced the U.S. FDA has approved ABRILADA as a biosimilar to Humira for the treatment of certain patients with rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn's disease, ulcerative colitis and plaque psoriasis. The company said, "Pfizer is working to make ABRILADA available to U.S. patients as soon as feasible based on the terms of our agreement with AbbVie (ABBV). Our current plans are to launch in 2023. We will provide further updates as the date approaches."

PFE

Pfizer

$37.28

0.73 (2.00%)

ABBV

AbbVie

$88.64

1.03 (1.18%)

  • 18

    Nov

  • 21

    Nov

  • 22

    Nov

  • 07

    Dec

PFE Pfizer
$37.28

0.73 (2.00%)

10/22/19
WEDB
10/22/19
NO CHANGE
Target $186
WEDB
Outperform
Ascendis Pharma price target lowered to $186 from $191 at Wedbush
Wedbush analyst Liana Moussatos lowered her price target for Ascendis Pharma (ASND) to $186 from $191 after competitors Opko Health (OPK) and Pfizer (PFE) announced topline results from a global Phase 3 trial evaluating somatrogon in pre-pubertal children with growth hormone deficiency. Given, Pfizer's role in registering and commercializing somatrogon, the analyst can see a potentially similar regulatory timeline to Ascendis, noting that the latter anticipates BLA and MAA submissions in the first half and second half of 2020, respectively. Nonetheless, Moussatos reiterates an Outperform rating on Ascendis shares as she remains positive on TC-hGH despite competition.
11/01/19
RAJA
11/01/19
UPGRADE
Target $24
RAJA
Outperform
Intellia Therapeutics upgraded to Outperform at Raymond James
Raymond James analyst Steven Seedhouse upgraded Intellia Therapeutics to Outperform from Market Perform with a $24 price target. In a research note to investors, Seedhouse says Intellia's NTLA-2001 is poised to benefit from the "heavy lifting" Pfizer (PFE) is doing commercially with Vyndaqel in ATTR-cardiomyopathy, adding that Intellia is also advancing manufacturing related activities in support of a Phase 1 trial for engineered cell program WT1-TCR in AML. The analyst also says Intellia's lead gene editing program, NTLA-2001 has "really good" primate data showing TTR knockdown potentially better than Alnylam's (ALNY) patisiran. He expects the market will already start to impute downstream clinical benefit for NTLA-2001 after only a few patients with initial TTR knockdown data, because of the collective data for Ionis Pharmaceuticals' (IONS) inotersen and Alnylam's patisiran showing knockdown is relevant.
11/06/19
PIPR
11/06/19
NO CHANGE
Target $70
PIPR
Neutral
Ionis Pharmaceuticals price target lowered to $70 from $75 at Piper Jaffray
Piper Jaffray analyst Tyler Van Buren lowered his price target on Ionis Pharmaceuticals (IONS) to $70 and kept his Neutral rating after its Q3 results, saying that while the quarter was "strong" thanks to the recent $250M upfront payment from Pfizer (PFE), results for its Tegsedi were "uninspiring". The analyst states that an acceleration in Tegsedi is needed soon for him to become more positive on the name ahead of the "potential Phase I/II OLE +natural history Huntington's study readouts next year."
11/12/19
PIPR
11/12/19
NO CHANGE
Target $185
PIPR
Overweight
Time to dismiss Solid Biosciences as Sarepta competitor, says Piper Jaffray
Piper Jaffray analyst Danielle Brill says that while she had dismissed Solid Biosciences' (SLDB) microdystophin gene therapy program as a competitive threat to Sarepta Therapeutics (SRPT), some investors worried that Solid could provide compelling data after adjusting protocol and moving up the dose. However, today's report of another clinical hold confirms that Solid's construct is toxic, indicating that Pfizer's (PFE) may to too, Brill tells investors in a research note. The analyst points out that both Solid and Pfizer use AAV9 and have had complement mediated serious adverse events after dosing just a few patients. Solid's program reaffirms her view that Sarepta's safety profile is differentiated. It is unlikely that the competition "is viable, let alone will ever catch up," says Brill. She keeps an Overweight rating on Sarepta Therapeutics with a $185 price target. The stock in midday trading is up 4% to $99.02 while Solid Biosciences is down 71% to $3.22.
ABBV AbbVie
$88.64

1.03 (1.18%)

10/10/19
STFL
10/10/19
NO CHANGE
Target $135
STFL
Buy
Reata Pharmaceuticals 'bold move' should be well received by Street, says Stifel
Stifel analyst Adam Walsh notes that in "a bold move" likely to be well received by the Street, Reata Pharmaceuticals (RETA) reacquired ex-U.S. rights to BARD, OMAV, and other Nrf2 activators from AbbVie (ABBV) for total deal consideration of $330M. Given AbbVie's lack of a significant renal franchise, the reacquisition of ex-U.S. BARD rights restores strategic flexibility to Reata and provides the opportunity to either find a more engaging development partner, go it alone ex-U.S., or sell the company outright, he contends. Further, the analyst believes the deal terms look "highly reasonable" relative to potential ex-U.S. BARD sales. Walsh has a Buy rating and $135 price target on Reata's shares.
10/30/19
WELS
10/30/19
UPGRADE
Target $20
WELS
Outperform
Wells Fargo upgrades Revance to Outperform, boosts target to $20
Wells Fargo analyst Jacob Hughes upgraded Revance Therapeutics (RVNC) to Outperform from Market Perform with a price target of $20, up from $12.50. After meeting with management, the analyst likes the setup for shares. Revance has a commercial-focused CEO with a history of shareholder value creation in aesthetics and a "catalyst rich" 12 months, Hughes tells investors in a research note. He believes the stock has "significant upside potential" and likes the cash pay nature of aesthetics. The multi-billion neurotoxins market will continue to expand, and disruption from the Allergan (AGN), AbbVie (ABBV) merger will create opportunities for Revance to take share, contends Hughes.
11/01/19
PIPR
11/01/19
NO CHANGE
Target $90
PIPR
Overweight
AbbVie price target raised to $90 from $81 at Piper Jaffray
Piper Jaffray analyst Christopher Raymond raised his price target for AbbVie to $90 from $81 saying this morning's Q3 results were stronger than anticipated. The stock in afternoon trading is up 3% to $81.70. While "there were puts and takes across the board," including Humira and Imbruvica upside along with a "big miss" for the hepatitis C virus franchise, AbbVie posted Q3 earnings and sales beats, Raymond tells investors a post-earnings research note. Combined with the announcement of the dividend getting a double-digit increase, the analyst continues to like the setup for the shares and remains a buyer with an Overweight rating.
11/15/19
GUGG
11/15/19
NO CHANGE
Target $228
GUGG
Buy
BeiGene price target raised to $228 from $205 at Guggenheim
Guggenheim analyst Michael Schmidt raised his price target for BeiGene (BGNE) to $228 from $205 saying FDA approval of Brukinsa over three months ahead of the action date provides additional validation of the company's strategy and ability to execute. He thinks Brukinsa's label in mantle cell lymphoma indicates a "potentially best-in-class" product profile with "nuanced differences" compared to AstraZeneca's (AZN) Calquence and "significantly better" than AbbVie's (ABBV) Imbruvica. The analyst maintains a Buy rating on BeiGene shares.

TODAY'S FREE FLY STORIES

MGTA

Magenta Therapeutics

$12.99

-0.14 (-1.07%)

05:03
12/06/19
12/06
05:03
12/06/19
05:03
Initiation
Magenta Therapeutics initiated  »

Magenta Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

ODT

Odonate Therapeutics

$33.29

-1.75 (-4.99%)

05:02
12/06/19
12/06
05:02
12/06/19
05:02
Initiation
Odonate Therapeutics initiated  »

Odonate Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KNSA

Kiniksa

$10.01

-0.1 (-0.99%)

05:00
12/06/19
12/06
05:00
12/06/19
05:00
Upgrade
Kiniksa rating change  »

Kiniksa assumed to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMED

Amedisys

$165.41

-1.22 (-0.73%)

04:58
12/06/19
12/06
04:58
12/06/19
04:58
Initiation
Amedisys initiated  »

Amedisys initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNY

Sanofi

$46.09

-0.49 (-1.05%)

04:56
12/06/19
12/06
04:56
12/06/19
04:56
Downgrade
Sanofi rating change  »

Sanofi downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 09

    Dec

CDEV

Centennial Resource Development

$3.41

0.06 (1.79%)

04:55
12/06/19
12/06
04:55
12/06/19
04:55
Downgrade
Centennial Resource Development rating change  »

Centennial Resource…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ECA

Encana

$3.93

-0.135 (-3.32%)

04:55
12/06/19
12/06
04:55
12/06/19
04:55
Downgrade
Encana rating change  »

Encana downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CDNS

Cadence Design

$65.77

-0.15 (-0.23%)

04:55
12/06/19
12/06
04:55
12/06/19
04:55
Conference/Events
Cadence Design management to meet with RBC Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

SPGI

S&P Global

$271.33

2.81 (1.05%)

04:55
12/06/19
12/06
04:55
12/06/19
04:55
Conference/Events
S&P Global management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 07

    Jan

04:55
12/06/19
12/06
04:55
12/06/19
04:55
Conference/Events
Wolfe Research healthcare analysts to hold an analyst/industry webcast »

Healthcare Analysts…

FTNT

Fortinet

$104.92

1.37 (1.32%)

04:55
12/06/19
12/06
04:55
12/06/19
04:55
Conference/Events
Fortinet management to meet with Oppenheimer »

Meetings with Management…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 09

    Dec

  • 12

    Dec

  • 08

    Jan

KMPR

Kemper

$73.65

-0.76 (-1.02%)

04:55
12/06/19
12/06
04:55
12/06/19
04:55
Conference/Events
Kemper management to meet with JMP Securities »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 11

    Dec

  • 12

    Dec

EXTR

Extreme Networks

$6.80

-0.08 (-1.16%)

04:55
12/06/19
12/06
04:55
12/06/19
04:55
Conference/Events
Extreme Networks management to meet with JMP Securities »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 10

    Dec

AXP

American Express

$118.31

0.32 (0.27%)

04:55
12/06/19
12/06
04:55
12/06/19
04:55
Conference/Events
American Express management to meet with William Blair »

Group Breakfast Meeting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

OPRT

Oportun Financial

$20.13

0.11 (0.55%)

04:55
12/06/19
12/06
04:55
12/06/19
04:55
Conference/Events
Oportun Financial management to meet with Jefferies »

Meeting to be held in Los…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

ILPT

Industrial Logistics Property Trust

$21.98

-0.515 (-2.29%)

, CBM

Cambrex

$59.99

(0.00%)

04:55
12/06/19
12/06
04:55
12/06/19
04:55
Hot Stocks
Industrial Logistics Property to replace Cambrex in S&P 600 at open on 12/6 »

Permira Advisors is…

ILPT

Industrial Logistics Property Trust

$21.98

-0.515 (-2.29%)

CBM

Cambrex

$59.99

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MNLO

Menlo Therapeutics

$4.20

0.2 (5.00%)

04:55
12/06/19
12/06
04:55
12/06/19
04:55
Conference/Events
Menlo Therapeutics management to meet with JMP Securities »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

MELI

MercadoLibre

$578.24

3.3 (0.57%)

04:55
12/06/19
12/06
04:55
12/06/19
04:55
Conference/Events
MercadoLibre management to meet with Piper Jaffray »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 17

    Dec

  • 17

    Dec

DSGX

Descartes Systems

$40.85

-1.59 (-3.75%)

04:55
12/06/19
12/06
04:55
12/06/19
04:55
Conference/Events
Descartes Systems management to meet with Wolfe Research »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

MPWR

Monolithic Power

$162.23

0.24 (0.15%)

04:55
12/06/19
12/06
04:55
12/06/19
04:55
Conference/Events
Monolithic Power management to meet with KeyBanc »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

ENLAY

Enel

$0.00

(0.00%)

04:55
12/06/19
12/06
04:55
12/06/19
04:55
Conference/Events
Enel management to meet with Morgan Stanley »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

WNC

Wabash

$15.51

0.17 (1.11%)

04:55
12/06/19
12/06
04:55
12/06/19
04:55
Conference/Events
Wabash management to meet with RBC Capital »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

04:55
12/06/19
12/06
04:55
12/06/19
04:55
Conference/Events
Macquarie to hold a conference »

Asia Internet, Media and…

AZPN

Aspen Technology

$120.26

-0.95 (-0.78%)

04:55
12/06/19
12/06
04:55
12/06/19
04:55
Recommendations
Aspen Technology analyst commentary  »

Aspen Technology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 12

    Dec

AAON

AAON

$49.14

0.78 (1.61%)

04:55
12/06/19
12/06
04:55
12/06/19
04:55
Conference/Events
AAON management to meet with Sidoti »

Meetings with Management…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.